Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
Chiara Pirrone(Ospedale Policlinico San Martino), Caterina De Grandis(Istituto Oncologico Veneto), Silvia Camera(Vita-Salute San Raffaele University), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Umberto Malapelle(Federico II University Hospital), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Anna Saborowski(Medizinische Hochschule Hannover), Alessandro Pastorino(Ospedale Policlinico San Martino), Fabian Finkelmeier(Goethe University Frankfurt), Federica Lo Prinzi(Campus Bio Medico University Hospital), Alessandro Parisi(Marche Polytechnic University), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Ricardo Roque, Giovanni Farinea(University of Turin), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Mario Scartozzi(University of Cagliari), Stephen L. Chan(Chinese University of Hong Kong), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Hong Jae Chon(CHA University Bundang Medical Center), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ingrid Garajová(University of Parma), Francesco Pepe(Federico II University Hospital), Chiara Pircher(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Cecilia Melo Alvim(Hospital de Santa Maria), Aitzaz Qaisar, Tomoyuki Satake(National Cancer Center Hospital East), Frederik Peeters, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Changhoon Yoo(Ulsan College), Jin Won Kim(Seoul National University Bundang Hospital), Il Hwan Kim(Inje University Haeundae Paik Hospital), Silvana Leo(Ospedale Vito Fazzi), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k